Acquired Partial Lipodystrophy Medication

1. Haque WA, Shimomura I, Matsuzawa Y, Garg A. Serum adiponectin and leptin levels in patients with lipodystrophies. J Clin Endocrinol Metab. 2002 May. 87(5):2395. [QxMD MEDLINE Link].

2. Capeau J, Magre J, Caron-Debarle M, et al. Human lipodystrophies: genetic and acquired diseases of adipose tissue. Endocr Dev. 2010. 19:1-20. [QxMD MEDLINE Link]. [Full Text].

3. Oliveira J, Freitas P, Lau E, Carvalho D. Barraquer-Simons syndrome: a rare form of acquired lipodystrophy. BMC Res Notes. 2016 Mar 18. 9:175. [QxMD MEDLINE Link]. [Full Text].

4. Misra A, Peethambaram A, Garg A. Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: report of 35 cases and review of the literature. Medicine (Baltimore). 2004 Jan. 83(1):18-34. [QxMD MEDLINE Link].

5. Caramaschi P, Biasi D, Lestani M, Chilosi M. A case of acquired partial lipodystrophy associated with POEMS syndrome. Rheumatology (Oxford). 2003 Mar. 42(3):488-90. [QxMD MEDLINE Link].

6. Cronin CC, Higgins TJ, Molloy M. Lupus, C3 nephritic factor and partial lipodystrophy. QJM. 1995 Apr. 88(4):298-9. [QxMD MEDLINE Link].

7. Walport MJ, Davies KA, Botto M, et al. C3 nephritic factor and SLE: report of four cases and review of the literature. QJM. 1994 Oct. 87(10):609-15. [QxMD MEDLINE Link].

8. Walker PD. Dense deposit disease: new insights. Curr Opin Nephrol Hypertens. 2007 May. 16(3):204-12. [QxMD MEDLINE Link].

9. Muto Y, Fujimura T, Kakizaki A, Tsuchiyama K, Kusakari Y, Aiba S. Adult-onset acquired partial lipodystrophy accompanied by rheumatoid arthritis. Case Rep Dermatol. 2015 Jan-Apr. 7 (1):70-4. [QxMD MEDLINE Link].

10. Sissons JG, West RJ, Fallows J, et al. The complement abnormalities of lipodystrophy. N Engl J Med. 1976 Feb 26. 294(9):461-5. [QxMD MEDLINE Link].

11. Savage DB, Semple RK, Clatworthy MR, et al. Complement abnormalities in acquired lipodystrophy revisited. J Clin Endocrinol Metab. 2009 Jan. 94(1):10-6. [QxMD MEDLINE Link].

12. Corvillo F, Lopez-Trascasa M. Acquired partial lipodystrophy and C3 glomerulopathy: dysregulation of the complement system as a common pathogenic mechanism. Nefrologia. 2018 May - Jun. 38(3):258-66. [QxMD MEDLINE Link]. [Full Text].

13. Kurugol Z, Ulger Z, Berk O, Tugral O. Acquired partial lipodystrophy associated with varicella. Turk J Pediatr. 2009 Nov-Dec. 51(6):617-20. [QxMD MEDLINE Link].

14. Hegele RA, Cao H, Liu DM, et al. Sequencing of the reannotated LMNB2 gene reveals novel mutations in patients with acquired partial lipodystrophy. Am J Hum Genet. 2006 Aug. 79(2):383-9. [QxMD MEDLINE Link]. [Full Text].

15. Hegele RA, Joy TR, Al-Attar SA, et al. Thematic review series: adipocyte biology. Lipodystrophies: windows on adipose biology and metabolism. J Lipid Res. 2007 Jul. 48(7):1433-44. [QxMD MEDLINE Link]. [Full Text].

16. Bhayana S, Hegele RA. The molecular basis of genetic lipodystrophies. Clin Biochem. 2002 May. 35(3):171-7. [QxMD MEDLINE Link].

17. Gao J, Li Y, Fu X, Luo X. A Chinese patient with acquired partial lipodystrophy caused by a novel mutation with LMNB2 gene. J Pediatr Endocrinol Metab. 2012. 25(3-4):375-7. [QxMD MEDLINE Link].

18. Vigouroux C, Magre J, Vantyghem MC, et al. Lamin A/C gene: sex-determined expression of mutations in Dunnigan-type familial partial lipodystrophy and absence of coding mutations in congenital and acquired generalized lipoatrophy. Diabetes. 2000 Nov. 49(11):1958-62. [QxMD MEDLINE Link].

19. Worman HJ, Bonne G. "Laminopathies": a wide spectrum of human diseases. Exp Cell Res. 2007 Jun 10. 313(10):2121-33. [QxMD MEDLINE Link]. [Full Text].

20. Adachi M, Asakura Y, Muroya K, Goto H, Kigasawa H. Abnormal adipose tissue distribution with unfavorable metabolic profile in five children following hematopoietic stem cell transplantation: a new etiology for acquired partial lipodystrophy. Clin Pediatr Endocrinol. 2013 Oct. 22(4):53-64. [QxMD MEDLINE Link]. [Full Text].

21. Hosokawa M, Shibata H, Hosokawa T, Irie J, Ito H, Hasegawa T. Acquired partial lipodystrophy with metabolic disease in children following hematopoietic stem cell transplantation: a report of two cases and a review of the literature. J Pediatr Endocrinol Metab. 2019 May 27. 32(5):537-41. [QxMD MEDLINE Link].

22. [Guideline] Brown RJ, Araujo-Vilar D, Cheung PT, et al. The diagnosis and management of lipodystrophy syndromes: a multi-society practice guideline. J Clin Endocrinol Metab. 2016 Dec. 101(12):4500-11. [QxMD MEDLINE Link]. [Full Text].

23. Demetriou K, Kallikas I, Zouvani I, et al. The pregnant patient with partial lipodystrophy developing acute renal failure--onset of de novo membranoproliferative glomerulonephritis. Nephrol Dial Transplant. 1998 Aug. 13(8):2121-4. [QxMD MEDLINE Link]. [Full Text].

24. Meyrier A. The patient with glomerulonephritis and lipodystrophy. Nephrol Dial Transplant. 1997 Jan. 12(1):226-7. [QxMD MEDLINE Link]. [Full Text].

25. Chopra S, Isaacs R, Mammen K, et al. Renal transplantation in a patient with Barraquer-Simons disease and mesangiocapillary glomerulonephritis type II. Nephrol Dial Transplant. 2000 Oct. 15(10):1723-4. [QxMD MEDLINE Link]. [Full Text].

26. Biasi D, Caramaschi P, Carletto A, Bambara LM. A case of acquired partial lipodystrophy associated with localized scleroderma and undifferentiated connective tissue disease. Rheumatol Int. 1999. 19(1-2):75-6. [QxMD MEDLINE Link].

27. Garg A. Lipodystrophies. Am J Med. 2000 Feb. 108(2):143-52. [QxMD MEDLINE Link].

28. Porter WM, O'Gorman-Lalor O, Lane RJ, Francis N, Bunker CB. Barraquer-Simons lipodystrophy, Raynaud's phenomenon and cutaneous vasculitis. Clin Exp Dermatol. 2000 Jun. 25(4):277-80. [QxMD MEDLINE Link].

29. Oswiecimska J, Ziora K, Geisler G, Dyduch A. Acquired partial lipodystrophy in an 11-year-old girl. Pediatr Int. 2008 Oct. 50(5):714-6. [QxMD MEDLINE Link].

30. Yavuz S, Acarturk TO. Acquired partial lipodystrophy with C3 hypocomplementemia and antiphospholipid and anticardiolipin antibodies. Pediatr Dermatol. 2010 Sep-Oct. 27(5):504-8. [QxMD MEDLINE Link].

31. Altay C, Secil M, Demir T, et al. Determining residual adipose tissue characteristics with MRI in patients with various subtypes of lipodystrophy. Diagn Interv Radiol. 2017 Nov-Dec. 23(6):428-34. [QxMD MEDLINE Link]. [Full Text].

32. Guettier JM, Park JY, Cochran EK, et al. Leptin therapy for partial lipodystrophy linked to a PPAR-gamma mutation. Clin Endocrinol (Oxf). 2008 Apr. 68(4):547-54. [QxMD MEDLINE Link].

33. Walker UA, Kirschfink M, Peter HH. Improvement of acquired partial lipodystrophy with rosiglitazone despite ongoing complement activation. Rheumatology (Oxford). 2003 Feb. 42(2):393-4. [QxMD MEDLINE Link]. [Full Text].

34. Sleilati GG, Leff T, Bonnett JW, Hegele RA. Efficacy and safety of pioglitazone in treatment of a patient with an atypical partial lipodystrophy syndrome. Endocr Pract. 2007 Oct. 13(6):656-61. [QxMD MEDLINE Link].

35. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007 Jun 14. 356(24):2457-71. [QxMD MEDLINE Link]. [Full Text].

36. Moran SA, Patten N, Young JR, et al. Changes in body composition in patients with severe lipodystrophy after leptin replacement therapy. Metabolism. 2004 Apr. 53(4):513-9. [QxMD MEDLINE Link].

37. Chong AY, Lupsa BC, Cochran EK, Gorden P. Efficacy of leptin therapy in the different forms of human lipodystrophy. Diabetologia. 2010 Jan. 53(1):27-35. [QxMD MEDLINE Link].

38. Chan JL, Lutz K, Cochran E, et al. Clinical effects of long-term metreleptin treatment in patients with lipodystrophy. Endocr Pract. 2011 Nov-Dec. 17(6):922-32. [QxMD MEDLINE Link]. [Full Text].

39. US Food and Drug Administration. BRISTOL-MYERS SQUIBB COMPANY Research and FOOD AND DRUG. Available at http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM377929.pdf. Accessed: 2014.

40. Al-Attar SA, Pollex RL, Robinson JF, et al. Quantitative and qualitative differences in subcutaneous adipose tissue stores across lipodystrophy types shown by magnetic resonance imaging. BMC Med Imaging. 2007 Mar 12. 7:3. [QxMD MEDLINE Link]. [Full Text].

41. Akinci B, Koseoglu FD, Onay H, et al. Acquired partial lipodystrophy is associated with increased risk for developing metabolic abnormalities. Metabolism. 2015 Sep. 64(9):1086-95. [QxMD MEDLINE Link].

42. Guenantin AC, Briand N, Bidault G, et al. Nuclear envelope-related lipodystrophies. Semin Cell Dev Biol. 2014 May. 29:148-57. [QxMD MEDLINE Link].

43. Nolis T. Exploring the pathophysiology behind the more common genetic and acquired lipodystrophies. J Hum Genet. 2014 Jan. 59(1):16-23. [QxMD MEDLINE Link].

44. Payapvipapong K, Niumpradit N, Nakakes A, Buranawuti K. A rare case of acquired partial lipodystrophy (Barraquer-Simons syndrome) with localized scleroderma. Int J Dermatol. 2014 Jan. 53(1):82-4. [QxMD MEDLINE Link].

45. Corvillo F, Ceccarini G, Nozal P, et al. Immunological features of patients affected by Barraquer-Simons syndrome. Orphanet J Rare Dis. 2020 Jan 10. 15(1):9. [QxMD MEDLINE Link]. [Full Text].

George T Griffing, MD Professor Emeritus of Medicine, St Louis University School of Medicine

George T Griffing, MD is a member of the following medical societies: American Association for Physician Leadership, American Association for the Advancement of Science, American College of Medical Practice Executives, American College of Physicians, American Diabetes Association, American Federation for Medical Research, American Heart Association, Central Society for Clinical and Translational Research, Endocrine Society, International Society for Clinical Densitometry, Southern Society for Clinical Investigation

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Arthur B Chausmer, MD, PhD, FACP, FACE, FACN, CNS Professor of Medicine (Endocrinology, Adj), Johns Hopkins School of Medicine; Affiliate Research Professor, Bioinformatics and Computational Biology Program, School of Computational Sciences, George Mason University; Principal, C/A Informatics, LLC

Arthur B Chausmer, MD, PhD, FACP, FACE, FACN, CNS is a member of the following medical societies: American Association of Clinical Endocrinologists, American College of Nutrition, American Society for Bone and Mineral Research, International Society for Clinical Densitometry, American College of Endocrinology, American College of Physicians, American College of Physicians-American Society of Internal Medicine, American Medical Informatics Association, Endocrine Society

Disclosure: Nothing to disclose.

George T Griffing, MD Professor Emeritus of Medicine, St Louis University School of Medicine

George T Griffing, MD is a member of the following medical societies: American Association for Physician Leadership, American Association for the Advancement of Science, American College of Medical Practice Executives, American College of Physicians, American Diabetes Association, American Federation for Medical Research, American Heart Association, Central Society for Clinical and Translational Research, Endocrine Society, International Society for Clinical Densitometry, Southern Society for Clinical Investigation

Disclosure: Nothing to disclose.

Amir E Harari, MD Staff Physician, Endocrinology Division, Instructor, Department of Clinical Medicine, Naval Medical Center at San Diego

Amir E Harari, MD is a member of the following medical societies: Alpha Omega Alpha, American Association of Clinical Endocrinologists, American College of Physicians, Endocrine Society

Disclosure: Nothing to disclose.

Waleed Aldhahi, MD, FRCPC Clinical Research Fellow, Department of Endocrinology, Joslin Diabetes Center, Harvard University

Disclosure: Nothing to disclose.

Robert A Gabbay, MD, PhD Associate Professor of Medicine, Division of Endocrinology, Diabetes and Metabolism, Laurence M Demers Career Development Professor, Penn State College of Medicine; Director, Diabetes Program, Penn State Milton S Hershey Medical Center; Executive Director, Penn State Institute for Diabetes and Obesity

Robert A Gabbay, MD, PhD is a member of the following medical societies: American Association of Clinical Endocrinologists, American Diabetes Association, and Endocrine Society

Disclosure: Novo Nordisk Honoraria Speaking and teaching; Merck Honoraria Speaking and teaching

Irina Lendel, MD Clinical Instructor in Endocrinology, Division of Endocrinology, Diabetes, and Metabolism, Milton S Hershey Medical Center

Disclosure: Nothing to disclose.

• Print this section
• Print the entire contents of
• Print the entire contents of article